

ELECTRONIC MEDICAL DOCUMENT INTEROPERABILITY (EMDI) DME eRx FHIR Workgroup Meeting Minutes

DATE:	11/20/2019	TIME: 2:00 PM	– 3:30 PM ET
LOCATION:	Teleconference		
DIAL-IN #	+1 (408) 650-3123	ACCESS CODE:	451 749 677
CHAIR:	Nandini Ganguly (Scope Infotech)	RECORDER:	Briana Barnes (Scope Infotech)

Attendees

CMS	AA HOMECARE	Apria	BINSONS
Christopher Lofts	Kim Brummett	Kenneth Hodel	Stephanie Legree
Candrea Smith		Zane Schott	
Paula Smith			
Denise St. Clair			
BRIGHTREE	COMPUTERS UNLIMITED	DARENA SOLUTIONS	ECLINICAL WORKS
Kim Catts	Joe Simanton	Pawan Jindal	Debora Wade
Gary Bartlett			
ELECTROMED	McKesson	REMOTE CARDIAC SERVICES	ROCKY MOUNTAIN MEDICAL
Stephanie Labelle	James Courtney	Mark Brown	Kelli Ore
ROTECH	SPECTRUM MEDICAL	SUPERCARE HEALTH	SCOPE INFOTECH
Joni Moss	Meredith Hendrie	Paula Dahl	Pallavi Talekar
Jackie DeVries			Ray Wilkerson
UNKNOWN			
Manbubul Haque			
Wayne Joyner			

Absentees

ADAPTHEALTH	AMERICAN COLLEGE OF SURGEONS	B.WELL	Britkare
Gwen Turner	Frank Opelka	Yelena Balin	Josh Britten
		Philips Johnson	
CLAIMSJUDGE	CONTRA COSTA HEALTH	DME Works	HOVEROUND
John Bright	Troy Kaji	Emil Di Motta	Debra Silvers
Christina Fox			
J. Michaels			
HOMECARE DELIVERED	LIBERTY MEDICAL SPECIALTIES	LINCARE	MEDSTAR
Sean Riley		Jeff Jackson	Peter Basch

MEDICAL SERVICE CO.	Microsoft	NATIONAL PARTNERSHIP FOR WOMEN & CHILDREN	PARACHUTE HEALTH
Josh Marx	James Fetters	Erin Mackay	David Gelbard
Michael McGill	Sachin Sinha		Josh Lee
	Ben Katzman		Matt Pestritto
	Jung Yoon		Jon Chan
	Blake Badolato		
	Todd Pliner		
REMOTE CARDIAC SERVICES	ResMed	THE VAN HALEM GROUP	UNITED HEALTHCARE
Mark Brown	Ryan Burke	Wayne Van Halem	Anupam Goel
	Larissa D'Andrea		
	Robert Jarrin		
	Rehana Nathwani		

NEW WAVE		
lames Fetters	Bob Dieterle (SME)	
Sachin Sinha		
Kate Wright		
		Minutes
1. Welcom		MINOTES
		he workgroup: Panel Discussion on ePrescribing and a
	nonstration of the DME eRx SMART on F	
	idini Ganguly introduced the panelist for t	
		Regulatory Affairs at American Association for Homecare (AA
	Homecare).	
		ent of Strategy and Business Development at SuperCare Health.
		r of Technology and Services at McKesson.
	Zane Schott: Director of IT Referra Stanbaria Lagracy Manager of Manager of Manager	
		dicare Reimbursement at Binsons.
		cting and Payer Regulations of Rocky Mountain Medical.
	x Panel Discussion	
		ok like in the real world? Please walk us through the process.
		different ways that the order comes in at Binsons - by hand (patier
		e fax machine (this can come into Binsons' system digitally as a
		but is still faxed from the provider's office), or by their ePrescribing
	platform that is managed by their s	
		ed the general methods by which orders/referrals come into Rocky
	Mountain Medical's office.	
		ify some challenges in the order/referral process with regards to the
	nes below?	
		ne accuracy of the order. There are very specific guidelines and
		order. Often times when the order comes into the supplier's
		urate per the policy guidelines and the Local Coverage
		are has established. Beyond this is the challenge of documentation
		der, the clinical documentation and lab values all need to be
		n does not retrieve all of the necessary data elements that the
		challenge is fulfilling the order: if a supplier retrieves an accurate
		question if the order was submitted to the patient and the patient is
		I challenge is audits: the supplier is faced with a huge risk of being
	audited before the supplier is paid.	
	i. Paula Dahl: One of the challenges	is the re-enforcing of the clinical guidelines and LCD requirements.
	Many providers/clinicians view the	order/referral process with a holistic view of the patient and not the
	view of the payer. Providers all ser	nd all the information about the patient without being aware that
	different payers have different asp	ects of coverage requirements. The auditing interpretation and
	review of this documentation can v	/ary.
c. Is it	possible for ePrescribing platforms to us	e Clinical Data Elements (CDEs)?
	i. James Courtney: Yes, I believe that	at this is possible to develop. He noted that most of the ordering
	solutions that submit patient demo	graphics and other patient information through the ordered
	products, transfer related data eler	ments to a notes field, which indicates that there is no place for
	these elements. This takes McKes	son's customer service representatives more time to read and
	process an order at intake.	
	•	the CMS CDEs for home oxygen therapy to include in the DMEhub
		e was push back where the CDEs were very comprehensive of a
		ny people wanted to know which CDEs should be incorporated to
		There was also some pushback to have ePrescribing platforms us
		nization with CMS' requirements and LCDs. This also speaks to the
		ge with the referral process where order routing in the ePrescribe
		rogram Interface (APIs)) can over burden the provider by making it

platform (using open Application Program Interface (APIs)) can over burden the provider by making it

difficult for providers to capture the DME. As a result, providers may want to ban the use of

 ePrescribing. ePrescribe platforms can use CDEs and will be great to utilize, there is a need to harmonize and simplify the actions that can be billable and collected participation. iii. David Bruinsma: Colonial Medical has an automated flow that looks for required diagnosis and will automatically reject an order if the CDEs are below threshold. Zane Scholt explained that their ePrescribe platforms built a platform of many rules for appropriation (documentation, use of DME, etc.) to allow for clinical evaluation and determination. The benefit eases the pain of entry and ePrescribe can achieve over 95 percent of orders being clean and deliverable. The CDEs have operational benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have supplies and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as "supporting documentation" and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These aproducts can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important to they the effeciscry in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other pay			Minutes
 harmonize and simplify the actions that can be billable and collected patient data. iii. David Bruinsma: Colonial Medical has an automated flow that looks for required diagnosis and will automatically reject an order if the CDEs are below threshold. Zane Schott explained that their ePrescribe platforms built a platform of many rules for appropriation (documentation, use of DME, etc.). to allow for clinical evaluation and determination. The benefit eases the pain of entry and ePrescribe can achieve over 95 percent of orders being clean and deliverable. The CDEs have operational benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson devolped their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering Troscess. It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Daht. It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency i			
 iii. David Bruinsma: Colonial Medical has an automated flow that looks for required diagnosis and will automatically reject an order if the CDEs are below threshold. Zane Schott explained that their ePrescribe platforms built a platform of many rules for appropriation (documentation, use of DME, etc.) to allow for clinical evaluation and determination. The benefit eases the pain of entry and ePrescribe can achieve over 95 percent of orders being clean and deliverable. The CDEs have operational benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRS) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation 'and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products are sporting to providers to work directly with CMS on what will be considered as 'met documentation requirement versus' contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. iii aportant to be versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. iiii and the ill care the efficiency in			
 automatically reject an order if the CDEs are below threshold. Zane Schott explained that their ePrescribe platforms built a platform of many rules for appropriation (documentation, use of DME, etc.) to allow for clinical evaluation and determination. The benefit eases the pain of entry and ePrescribe can achieve over 95 percent of orders being clean and deliverable. The CDEs have operational benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and eCrome easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do no thave CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as 'met documentation requirements' if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These process. It is important for providers to work directly with (NS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing latform where they can have a rule engine that can be engineered to mate that can advit with documentation returned' aso the documentation requiremen			
 ePrescribe platforms built a platform of many rules for appropriation (documentation, use of DME, etc.). to allow for clinical evaluation and determination. The benefit eases the pain of entry and ePrescribe can achieve over 95 percent of orders being clean and deliverable. The CDEs have operational benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-astep process. It is important for providers to work directly with CMS on what will be considered as "met documentation requirement" versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: Its important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing form where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will use all audits with documentati			
 to allow for clinical evaluation and determination. The benefit eases the pain of entry and ePrescribe can achieve over 95 percent of orders being clean and deliverable. The CDEs have operational benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for approcess for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus' contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing altorm where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation reture 'as not met documentation requirements. This can be done with Medicare support and outdance. e. How can CMS help educate medical reviewers on CDEs that are use			
 can achieve over 95 percent of orders being clean and deliverable. The CDEs have operational benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as 'met documentation requirements'' if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a nue engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation requirement's is not meet occumentation requirement's in the cDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were and yperscribe ap following the CDEs, will this document be considered to that was asked from this audience was 'when a document is cre			
 benefits that guide processes and allow non-clinicians to enter patient information and can be evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiancy in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and dher payer guidelines. As a result, suppliers mill see less issues and audits with documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribe apf following the CDEs, will			
 evaluated by the clinicians; the rules make the burden of entry and compliance easier. iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be encessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to mate Apolicy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes that the CDEs and atrice requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the answer for this audience was when a document is created in			
 iv. Kim Brummett: Not all ePrescribe platforms incorporate CDEs since some of them have an order generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus' contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returmed 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transitioned to the electronic platform. At one of AA Homeccar's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integr			
 generator. It will be beneficial to have suppliers and providers incorporate the CDEs. v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahi: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 ther			
 v. James Courtney: McKesson developed their own APIs and has direct integration with Electronic Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as 'met documentation requirements'' if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience was 'when a doc			
 Medical Records (EMRs) system and these EMRs do not have CDEs. This causes information to be transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representations of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is and prescribe ap following the CDEs, will this document of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency			
 transmitted as 'supporting documentation' and incorporated in a notes field. Zane Schott agrees that the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as "met documentation requirement" versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and acide requirements will need to be revised at transitioned for the equestions that was asked from this audience was 'when a document is created in an ePrescribe ap following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with acopting CDEs. The ePrescribe ap following the CDEs, will this document be considered the e			
 the CDEs should be required, so relative information does not end up being considered long extensive notes. d. Will CDEs be considered as "met documentation requirements" if it used? Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as "met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. a. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the question shat was asked from this audience was 'when a document is created in an ePrescrib application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescrib p			
 notes. d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahi: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the question shat was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR			
 d. Will CDEs be considered as "met documentation requirements" if it used? i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDS), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returmed 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform ne			
 i. Kelli Ore: Incorporating CDEs will assist with suppliers meeting the documentation requirements, but it should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescri		۱ ۱۷/۱	
 should be some product categories that will be necessary for additional guidance for ordering. These products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency with CDEs and its engineer to including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 		J. VVI	
 products can include power mobility devices (PMDs), since it is a two-step process for the ordering process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 process. It is important for providers to work directly with CMS on what will be considered as 'met documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the question sthat was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application. ii. Paula Dahl: The ePrescribe platform need to establish consistency and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 documentation requirement' versus 'contemplating medical records, if ePrescribing is a mandatory platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency and suppliers to adopt this application. 			
 platform to be utilized to order equipment. ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 ii. Paula Dahl: It is important to have the ePrescribe platform incorporate CDEs and be accepted by CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 CMS. The CDEs should create the efficiency in the ePrescribing platform where they can have a rule engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 engine that can be engineered to meet Medicare and other payer guidelines. As a result, suppliers will see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 see less issues and audits with documentation returned 'as not met documentation requirements. This can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 can be done with Medicare support and guidance. e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 e. How can CMS help educate medical reviewers on CDEs that are used? i. Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 Kim Brummett: CMS need to make a policy of the transition to ePrescribing. There is a lot of program integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 	e	e. Ho	
 integrity, but without the policy changes then the CDEs will never be fully implemented. All of the LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 LCDs and article requirements will need to be revised and transitioned to the electronic platform. At one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 one of AA Homecare's CMS In-services in 2018 there were many presentations from representatives of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 of applications with an audience of representatives from program integrity. One of the questions that was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 was asked from this audience was 'when a document is created in an ePrescribe app following the CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
 CDEs, will this document be considered the face-to-face or the clinical documentation' and the answer for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application should be considered an extent of the EMR to incline providers and suppliers to adopt this application. ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			was asked from this audience was 'when a document is created in an ePrescribe app following the
 should be considered an extent of the EMR to incline providers and suppliers to adopt this application. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its 			
ii. Paula Dahl: The ePrescribe platform need to establish consistency amongst reviewers. Often times the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its			for this question was no. This will be a challenge with adopting CDEs. The ePrecribing application
the suppliers becomes the medium of medical reviewers and the physician and they are left with challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its			should be considered an extent of the EMR to incline providers and suppliers to adopt this application.
challenging the physicians on their clinical judgement of DMEs and requirements (i.e., including specific verbiage in their documentation). If they were able to establish consistency with CDEs and its			
specific verbiage in their documentation). If they were able to establish consistency with CDEs and its			
and an annual fact through the first such a state for the second state of the second s			
			order generation, then it will be less subjectivity in the medical reviewer opinions. They can take away
ambiguity and create consistency by establishing CDEs in the ePrescribing and by educating the			
reviewers of accepting the documentation billed within the ePrescribe platform.			
iii. Zane Schott: Believes that CDEs will be the largest success factors on the operational needs of the			
suppliers to accurately provide the equipment for their patients in a timely manner. The determinant			
data should be retrieved through open APIs. Open APIs just mean that systems can easily talk to			
systems in a common easy to understand language. Medicare should be supportive and reflection of			
the rest of the healthcare systems (i.e., ePrescribe Medication and ePrescribe related Computerized			
Physician Order Entry (CPOE)), in which DME ePrescribe system should not be treated any			
differently. These systems should include pre-defined sets of data that are determinant and			
appropriate for use to advance the communication that benefits all including the patient. CMS can help			
by supporting standards, supporting necessary information compliance, and helping shepherd the			
process to allow the independent marketplace to interact and interoperate to get to solutions. This has			process to allow the independent marketplace to interact and interoperate to get to solutions. This has

	Minutes
	worked in other unfunded CMS mandate with the forcing of data related care plans for the Long Term
	Post Acute Care (LTPAC) communities.
f.	 What are the challenges associated with updating and maintaining Local Coverage Determinations (LCDs)? i. Kelli Ore: LCD requires suppliers to individually educate every physician that are referring orders. The supplier has to educate each physician on what has changed in an LCD or policy article, and how it may impact their referral/order prescribing ability. A CMS adoption of an ePrescribing platform is an approved list of ePrescribe platform that maintain and completes the update of the policy changes that
	get pushed to the physician. This eliminate the burden on the DME suppliers when educating physicians on the appropriate documentation and allows the physician to see these updates through the ePrescribe platform. ii. Stephanie Legree: That CDEs eliminate the supplier asking for appropriate documentation and
	provide insight that CMS is asking for the documentation, since suppliers receive backlash from their referral sources when requesting information. The CDEs follows the LCDs, but it is an extensive process to change the LCDs, which can be challenge.
g.	If a patient doesn't meet coverage criteria, is there any guidance for physicians to complete the order? i. Stephanie Legree: We will currently use resources on the DME Medicare Administrator Contractors (MACs) website (i.e., LCDs or Program Integrity Manual) to provide to the physicians. Suppliers will
	manually educate the physicians with the issues or what may be missing in the coverage on the documentation that they receive. The CDEs can help with this guidance, since it will display what is going on at every point of the order (i.e., DMEhub tells if the oxygen order qualifies right away).
	ii. James Courtney: This is the same for me. McKesson's authorization specialist will work with the payer and order physician. These specialists offer guidance or education to the physician, which is usually done over the phone or via fax. Some of the ePrescribe solutions providers insurance, coverage, or decision support within their user interface (UI) at the time the order is placed on the clinician end. This solution is really effective.
h.	What is the biggest barrier for CDEs adoption? How can CMS help to adopt the CDEs?
	i. Paula Dahl: The biggest barrier adoption is related to EHRs in which physicians will have to duplicate efforts with the EHR and ePrescribe platform. The provider has to remember which ordering system of application to use for their different suppliers. A universal platform that can be easily integrated with EHRs will increase the adoption rate.
	 Kelli Ore: There will be a greater adoption if more of the ePrescribing platforms, physicians, and EHRs knew that CDEs is acceptable by CMS.
	iii. Kim Brummett: If the CDEs are not mandatory then they will not be incorporated. She noted that the PMD CDEs were created years ago, but no EHRs incorporated these CDEs. They need to be mandatory for physicians, hospitals, and stand-along ePrescribing. They should also remove all the manual cumbersome documentation requirements. Pallavi Talekar asked CMS considered including these types of documentation in the patient over paperwork or provider burden programs. Kim Brummett replied that she believes that CMS Program Integrity that can oversee is being concerned, but CMC patients to the patient over paper work or provider burden programs. Kim Brummett replied that she believes that CMS Program Integrity that can oversee is being concerned, but CMC patients the patient over paper work or provider burden programs.
	but CMS policy will have to revise items such as LCD and National Coverage Determinations (NCDs) to proceed with this. Kim Brummett suggested for CMS policy representatives to get involved in these discussions in order to make ePrescribing and CDEs to become more successful.
i.	 How would physicians address coverage criteria when documents are created outside of EHR? i. Zane Schott: There are cases where the coordination of care where other therapists involved where the documentation can lie outside their traditional primary clinical system, which can be difficult for the physician groups that do not have Direct Secure Messaging, network access, or storage for documentation. The ePrescribe solutions can take external sources for a complete and accurate order.
j.	 What are some challenges that current ePrescribing platforms face? i. James Courtney: Suppliers are now required to connect with multiple ePrescribe solutions, and it can be cumbersome to log into multiple portals. The lack of connectivity features of the ePrescribe solution roadmap and they need a higher priority of platform integration.
	ii. Zane Schott: There is an operational challenge with multiple solutions and tools (i.e. hospital lab system, EHR system, etc.). The suppliers should move toward APIs to remove the burden for suppliers. These challenges will resolve in the next few years when the current APIs mature.
k.	How do we overcome the challenge of coverage requirements through an ePrescribing platform?

		Minutes
		i. Kelli Ore: The burden currently resides on the DME suppler to individually educate physicians. Physician believe that it is a DME supplier's requirement rather than a CMS requirement. I suggest building into the ePrescribe platform, like a questionnaire, and if the physician does not qualify then the platform directs the physician on information (i.e., policy articles) to understand why their patient does not qualify. CMS should do an integrated data mining from these platforms to provide information
		on the same scale of the CPT to a DME supplier. ii. Paula Dahl: One should require adoption of the CDEs into the order to channel all physicians within this channel and provide education (i.e., coverage criteria). It is suggested to have a platform to
		remind the physicians of such requirements. The ePrescribe platform can provide the opportunity to educate physicians on the CDEs that is beneficial. This can assist CMS with educating the entire provider community. iii. Kim Brummett: CMS can provide incentives to those implementing CDEs.
	I.	 What challenges do DME Suppliers face finding hospitals or providers with ePrescribing functionality? i. Stephanie Legree It is difficult for physician groups to adopt the ePrescribing platform because it may not integrate into their system. It was another challenge of the different logins for each platform. Some platforms that have not adopted CDEs are difficult to get certain information (i.e., medical records) from. This is difficult to obtain through some of the ePrescribing platforms for the physician.
	m.	 What kind of challenges does suppliers face when they use a health IT system for order receiving and additional documentation requests? i. Stephanie Legree: This is the same response from the previous question (login from different platform) and request of medical information of having the medical record to address medical necessity. Each
		 time the order is sent through the ePrescribe platform then the providers are charged for many of these transactions. Kim Brummett said that it is a per transaction fee that suppliers pay, but they do not pay for the application. ii. James Courtney: The cost per transaction continues to rise, which is why McKesson is developing their own API solutions and direct connections.
	n.	How does Open APIs address these challenges? How does DME eRx workflow solve a part of these challenges?
		 i. James Courtney: The open APIs allow for a broader range of developers to connect and test solutions. There is also more power to the patient (i.e., APIs allows the aggregation of the patient information that can assist the care giver). ii. Zane Schott: Open APIs allow the follow-on benefit like the re-certification necessary for an order.
3.	см	Open APIs benefit the longevity of the ongoing patient care. ART on FHIR App Demo
э.	a.	David Bruinsma and Zane Schott provided a demonstration of the DME eRx SMART on FHIR App.
	b.	The SMART on FHIR App utilize real data using API to work with ePrescribing and supplier solutions.
	С.	The demonstration of the SMART on FHIR App provide an assimilation the launch of the DME inside the EHR.
	0.	The provider will choose the order that they want to submit. This launches a Clinical Decision Support (CDS) Hooks server and its endpoint, and determines the documentation requirements links (i.e., provide links to LCDs and SMART app launch link).
	d.	Once the clinicians click the SMART App button, then this will launch the SMART app and it will display the FHIR questionnaire. This questionnaire is usually pre-filled with elements of the home oxygen therapy is derived from CMS CDEs. This questionnaire loads from a HAPPI FHIR server.
	e.	Zane Schott explained that the background of the SMART on FHIR App includes Keycloak for authentication, FHIR HAPI server (can be used as an EHR sandbox), CDS Hooks, Coverage Requirement Discovery (CRD) and Document Template Rules (DTR).
	f.	Zane Schott provided an overview of the DME eRx workflow. Mark Brown asked where the physician signature authenticated or owned in the workflow. Zane Schott replied that electronic signature can occur in the hub using a mobile iOS, android, or web signature. If the provider does not utilize the hub, then the supplier may need to do the appropriate follow-up with the provider.
	g.	DMEhub has critical date elements and rules that can be configured dynamically. DMEhub consists of various payer and CMS rules (i.e., CDEs). DMEhub also has available APIs and the ability to support to pilots and customers.
4.	Roi	und Table
	a.	Nandini Ganguly encourage all workgroup participants to visit the EMDI environmental scan.

Minutes	
b. The upcoming DME eRx Workgroup will be January 30,2020	
c. The EMDI team is planning a virtual Connectathon for DME eRx on 01/14/2020 and 01/21/2020.2020.	
d. The DME Order FHIR Implementation Guide will be going through Health Level Seven (HL7) January 2020	
ballot.	
,	
DECISIONS MADE	
1. None.	
Risks	
1. None discussed.	
ISSUES	
1. None noted.	

Al#	ACTION ITEMS	RESPONSIBLE PERSON	DUE DATE
	None noted.		

* Action Item numbers are assigned from an internal-facing list and may not be sequential between meetings.

Next Meeting: Tuesday, 01/28/2019, 3:00 PM ET